CA2162610A1 - Peptides utiles pour arreter la proliferation de cellules souches myeloides et traiter le choc septique - Google Patents

Peptides utiles pour arreter la proliferation de cellules souches myeloides et traiter le choc septique

Info

Publication number
CA2162610A1
CA2162610A1 CA002162610A CA2162610A CA2162610A1 CA 2162610 A1 CA2162610 A1 CA 2162610A1 CA 002162610 A CA002162610 A CA 002162610A CA 2162610 A CA2162610 A CA 2162610A CA 2162610 A1 CA2162610 A1 CA 2162610A1
Authority
CA
Canada
Prior art keywords
lys
ala
pro
arg
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002162610A
Other languages
English (en)
Inventor
Robert N. Moore
Robert Kreisberg
Melinda Detrick Kreisberg
Hal E. Broxmeyer
Scott Cooper
Li Lu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Corp Technologies Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2162610A1 publication Critical patent/CA2162610A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Des peptides contenant la séquence Ala-Lys-Pro-Arg présentent des effets suppresseurs sur la prolifération d'un large éventail de cellules souches myélopoïétiques. Dans un mode de réalisation préféré, le peptide présente la séquence Glu-Thr-Val-Ile-Met-Lys-Ala-Lys-Pro-Arg-Ala-Asn-Phe-Pro. Les peptides de l'invention sont utiles dans le traitement de troubles hyperprolifératifs myélopoïétiques, et dans la production de cellules myéloïdes contre une détérioration induite par chimiothérapie et par rayonnement. Des peptides contenant la séquence Ala-Lys-Pro-Arg sont également utiles dans le traitement du choc septique induit par endotoxine.
CA002162610A 1993-05-20 1994-05-18 Peptides utiles pour arreter la proliferation de cellules souches myeloides et traiter le choc septique Abandoned CA2162610A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6572293A 1993-05-20 1993-05-20
US065,722 1993-05-20
PCT/US1994/005773 WO1994028013A1 (fr) 1993-05-20 1994-05-18 Peptides de suppression de la proliferation de cellules souches myeloides et de traitement du choc septique

Publications (1)

Publication Number Publication Date
CA2162610A1 true CA2162610A1 (fr) 1994-12-08

Family

ID=22064655

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002162610A Abandoned CA2162610A1 (fr) 1993-05-20 1994-05-18 Peptides utiles pour arreter la proliferation de cellules souches myeloides et traiter le choc septique

Country Status (4)

Country Link
EP (1) EP0698039A1 (fr)
JP (1) JPH08510745A (fr)
CA (1) CA2162610A1 (fr)
WO (1) WO1994028013A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6593372B2 (en) 1996-11-13 2003-07-15 Cold Spring Harbor Laboratory Therapeutic uses for nitric oxide inhibitors
WO1998020865A2 (fr) * 1996-11-13 1998-05-22 Cold Spring Harbor Laboratory Utilisations therapeutiques d'inhibiteurs d'oxyde nitrique
US6372796B1 (en) 1996-11-13 2002-04-16 Cold Spring Harbor Laboratory Therapeutic uses for nitric oxide inhibitors
FR2903311B1 (fr) * 2006-07-10 2012-06-15 Centre Nat Rech Scient Utilisation de ligands du recepteur h4 de l'histamine pour proteger les progeniteurs hematopoietiques contre la toxicite hematologique des agents chimiotherapeutiques
CN113952446B (zh) * 2021-09-03 2023-12-05 河南省医药科学研究院 生物活性肽在抑制骨髓毒性中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI77875C (fi) * 1982-11-26 1989-05-10 Nyegaard & Co As Foerfarande foer framstaellning av nya terapeutiskt anvaendbara peptider.
IL77323A0 (en) * 1985-12-13 1987-01-30 Yeda Res & Dev Immunizing preparation comprising tuftsin or an analog thereof
US5149544A (en) * 1989-11-13 1992-09-22 Research Corporation Technologies, Inc. Method of inhibiting progenitor cell proliferation

Also Published As

Publication number Publication date
JPH08510745A (ja) 1996-11-12
EP0698039A1 (fr) 1996-02-28
WO1994028013A1 (fr) 1994-12-08

Similar Documents

Publication Publication Date Title
Singh et al. Definition of a specific interaction between the early T lymphocyte activation 1 (Eta-1) protein and murine macrophages in vitro and its effect upon macrophages in vivo.
Leizer et al. Cytokine regulation of colony-stimulating factor production in cultured human synovial fibroblasts: I. Induction of GM-CSF and G-CSF production by interleukin-1 and tumor necrosis factor
Fischer et al. Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia.
Bagby et al. Interleukin 1 stimulates granulocyte macrophage colony-stimulating activity release by vascular endothelial cells.
EP0536275B1 (fr) Inhibiteurs de croissance de tumeurs derives de tissus, procedes de preparation et utilisations desdits inhibiteurs
RU2292352C9 (ru) Ингибитор и стимулятор пролиферации стволовой клетки и их использование
Soda et al. Manifestations of cancer cachexia induced by colon 26 adenocarcinoma are not fully ascribable to interleukin‐6
EP0378364A2 (fr) Analogues de PF4 et leurs fragments et compositions pharmaceutiques les contenant
WO1992002240A2 (fr) Compositions et procedes nouveaux pour le traitement des maladies angiogeniques
US5730976A (en) Method for treating macrophage pathogen infections by TGF-B antagonists
US5792450A (en) Purified human CSF-1
US6355619B1 (en) Peptide tumor cell growth inhibitors
AU7844794A (en) Methods for stimulating interleukin-6 synthesis and inducing thrombocytopoiesis using oncostatin m
JP2846629B2 (ja) 組換えコロニー刺激因子−１を含んで成る医薬組成物
CA2162610A1 (fr) Peptides utiles pour arreter la proliferation de cellules souches myeloides et traiter le choc septique
EP0341273B1 (fr) Substances biologiques et procedes de production et d'utilisation de ces substances biologiques en therapeutique
CA2040969C (fr) Utilisation du facteur de croissance transformant de type beta pour accroitre le nombre de macrophages et de granulocytes
KR19990066997A (ko) 조혈성 간세포의 이동 방법
AU691085B2 (en) Anti-inflammatory CD14 polypeptides
FI91484C (fi) Menetelmä uuden solun kasvua säätelevän tekijän, onkostatiini M:n valmistamiseksi
JP2011137019A (ja) インターロイキン−３から誘導されるレトロ−インベルソペプチド
JPH04506818A (ja) 造血細胞の成熟
US6403553B1 (en) Use of polypeptides for treating thrombocytopenia
JPH09510688A (ja) Ｃｘｃインタークリン分子のペプチド阻害剤
AU638473B2 (en) Promoters of colony stimulating factor activity

Legal Events

Date Code Title Description
FZDE Discontinued
FZDE Discontinued

Effective date: 19980519